BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share in a registered direct offering expected to generate approximately $4 million in gross proceeds. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share, potentially generating approximately $4 million in additional gross proceeds if fully exercised for cash.

The offering is expected to close on or about Sept. 30, 2026, subject to customary closing conditions, with Rodman & Renshaw LLC acting as exclusive placement agent. Lantern Pharma intends to use the net proceeds for working capital and other general corporate purposes. The unregistered warrants will become exercisable subject to stockholder approval and will expire five years following that approval.

To view the full press release, visit https://ibn.fm/PCJbt

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN